We are live on ! Find out more
XENE icon

Xenon Pharmaceuticals
XENE

204 hedge funds and large institutions have $3.33B invested in Xenon Pharmaceuticals in 2023 Q4 according to their latest regulatory filings, with 46 funds opening new positions, 86 increasing their positions, 51 reducing their positions, and 19 closing their positions.

New
Increased
Maintained
Reduced
Closed

142% more first-time investments, than exits

New positions opened: 46 | Existing positions closed: 19

69% more repeat investments, than reductions

Existing positions increased: 86 | Existing positions reduced: 51

59% more capital invested

Capital invested by funds: $2.1B → $3.33B (+$1.23B)

56% more funds holding in top 10

Funds holding in top 10: 9 → 14 (+5)

13% more funds holding

Funds holding: 180 → 204 (+24)

2.19% more ownership

Funds ownership: 95.63% → 97.83% (+2.2%)

4% less call options, than puts

Call options by funds: $39M | Put options by funds: $40.6M

Holders
204
Holders Change
+24
Holders Change %
+13.33%
% of All Funds
2.97%
Holding in Top 10
14
Holding in Top 10 Change
+5
Holding in Top 10 Change %
+55.56%
% of All Funds
0.2%
New
46
Increased
86
Reduced
51
Closed
19
Calls
$39M
Puts
$40.6M
Net Calls
-$1.6M
Net Calls Change
+$6.69M

Top Buyers

1
Wellington Management Group
Wellington Management Group
Massachusetts
+$86M
2
Fidelity Investments
Fidelity Investments
Massachusetts
+$49.6M
3
BlackRock
BlackRock
New York
+$38M
4
FLAM
First Light Asset Management
Minnesota
+$36.9M
5
T. Rowe Price Investment Management
T. Rowe Price Investment Management
Maryland
+$31.5M

Top Sellers

1
BI
BVF Inc
California
-$33.1M
2
NIP
Nicholas Investment Partners
California
-$27.1M
3
Marshall Wace
Marshall Wace
United Kingdom
-$22.1M
4
SC
Samlyn Capital
New York
-$18.7M
5
B
Braidwell
Connecticut
-$16.1M
Name Holding Trade Value Shares
Change 		Change in
Stake
Two Sigma Advisers
51
Two Sigma Advisers
New York
$11.6M +$6.64M +187,800 +289%
ABG
52
Ally Bridge Group
New York
$11.1M -$883K -25,000 -9%
Westfield Capital Management
53
Westfield Capital Management
Massachusetts
$10.9M +$8.39M +237,495 New
State Street
54
State Street
Massachusetts
$10.5M +$518K +14,670 +7%
TLP
55
Tri Locum Partners
New York
$10.4M +$1.9M +53,809 +31%
AG
56
Algert Global
California
$10M +$3.14M +88,833 +69%
PI
57
Putnam Investments
Massachusetts
$9.93M +$1.54M +43,609 +25%
WP
58
Woodline Partners
California
$9.05M +$1.87M +53,002 +37%
PHS
59
PFM Health Sciences
California
$8.88M +$4.04M +114,269 +145%
New York State Common Retirement Fund
60
New York State Common Retirement Fund
New York
$8.77M +$201K +5,680 +3%
Axa
61
Axa
France
$8.65M -$160K -4,542 -2%
VPC
62
Vestal Point Capital
New York
$8.06M +$6.18M +175,000 New
Russell Investments Group
63
Russell Investments Group
United Kingdom
$8.03M +$173K +4,898 +3%
ECM
64
ExodusPoint Capital Management
New York
$7.61M -$6.87M -194,571 -54%
Ensign Peak Advisors
65
Ensign Peak Advisors
Utah
$7.57M – – –
SCM
66
Silverarc Capital Management
Massachusetts
$7.52M +$3.86M +109,172 +202%
LGM
67
Logos Global Management
California
$6.91M -$10.6M -300,000 -67%
BM
68
Bridger Management
New York
$6.76M +$5.19M +146,800 New
Bank of America
69
Bank of America
North Carolina
$6.14M +$334K +9,445 +8%
DnB Asset Management
70
DnB Asset Management
Norway
$5.82M +$163K +4,605 +4%
Swiss National Bank
71
Swiss National Bank
Switzerland
$5.7M +$428K +12,100 +11%
Barclays
72
Barclays
United Kingdom
$5.16M +$3.62M +102,469 +1,076%
NFGH
73
Nan Fung Group Holdings
Hong Kong
$4.91M – – –
BAMCO Inc
74
BAMCO Inc
New York
$4.61M – – –
Assenagon Asset Management
75
Assenagon Asset Management
Luxembourg
$4.59M -$1.69M -47,962 -32%
1 2
3
4 5

XENE Hedge Fund Activity: Q4 2023 in Review

204 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Xenon Pharmaceuticals (XENE) for Q4 2023, worth a combined $3.33B — up 59% from $2.1B a quarter earlier.

Buyers outnumbered sellers: 46 funds opened new XENE positions and 19 closed out — a net gain of 27 holders — while 86 added to existing stakes and 51 trimmed.

The largest buyer was Wellington Management Group, adding an estimated $86M. The largest seller was BVF Inc, cutting an estimated $33.1M.

  • 204 institutional investors held Xenon Pharmaceuticals (XENE) as of Q4 2023, up from 180 in Q3 2023.
  • Funds reported $3.33B of Xenon Pharmaceuticals stock for Q4 2023, up 59% quarter-over-quarter.
  • 46 funds opened new Xenon Pharmaceuticals positions in Q4 2023 and 19 closed out, a net change of +27 holders.
  • The largest Xenon Pharmaceuticals buyer in Q4 2023 was Wellington Management Group, an estimated $86M added.
  • The largest Xenon Pharmaceuticals seller in Q4 2023 was BVF Inc, an estimated $33.1M sold.

Based on aggregated 13F filings for Q4 2023.